End-stage renal disease is associated with increased post endoscopic retrograde cholangiopancreatography adverse events in hospitalized patients

doi:10.3748/wjg.v24.i41.4691

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 24, Issue 41

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4902)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

408

HTML

2592

Figures (1-1)

154

Tables (1-3)

166

Sum=3320

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

576

Download

1006

Sum=1582

Nov 7, 2018 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Nov 7, 2018; 24(41): 4691-4697
Published online Nov 7, 2018. doi: 10.3748/wjg.v24.i41.4691

Table 1 Baseline characteristics of 492175 nationally estimated discharges in the Nationwide Inpatient Sample from 2011 to 2013 who underwent endoscopic retrograde cholangiopancreatography comparing end-stage renal disease and chronic kidney disease to control group without renal disease n (%)

	ESRD, n = 7347	Control, n = 445424	P value	CKD, n = 39403	P value
Age, mean (SE), yr	65.5 (0.42)	58 (0.12)	< 0.001	75.35 (0.18)	< 0.001
Female	3477 (47.3)	271300 (61)	< 0.001	17626 (44.7)	< 0.001
Race			< 0.001		< 0.001
White	3221 (43.8)	280738 (63)		26905 (68.3)
Black	1520 (20.7)	36875 (8.3)		3517 (8.9)
Hispanic	1467 (20)	68492 (15.4)		3729 (9.5)
Asian/Pacific Islander	454 (6.2)	14081 (3.2)		1466(3.7)
Native American	105 (1.4)	2828 (0.6)		185 (0.5)
Other	235 (3.2)	14928 (3.3)		982 (2.5)
Missing	344 (4.7)	27483 (6.2)		2619 (6.6)
Charlson comorbidity index			< 0.001		< 0.001
0	0	203229 (45.6)		0 (0)
1	0	104584 (23.5)		0 (0)
2	975 (13.3)	55808 (12.5)		6417 (16.3)
> 2	6372 (86.7)	81804 (18.4)		32986 (83.7)
Coagulopathy	668 (9)	15102 (3.4)	< 0.001	2633 (6.7)	< 0.001
ERCP indication			< 0.001		< 0.001
Diagnostic	1990 (27)	102074 (22.9)		9493 (24.1)
Therapeutic	5257 (73)	343350 (77.1)		29910 (75.9)
Health insurance			< 0.001		< 0.001
Medicare	5655 (77)	189044 (42.7)		31759 (80.7)
Medicare	923 (9.9)	59219 (13.4)		1718 (4.4)
Private	827 (11.3)	142807 (32.3)		4766 (12)
Self-pay	40 (0.5)	32785 (7.4)		463 (1.2)
Others	92 (1.3)	18822 (4.2)		670 (1.7)

ESRD: End-stage renal disease; CKD: Chronic kidney disease; ERCP: Endoscopic retrograde cholangiopancreatography.

Citation: Sawas T, Bazerbachi F, Haffar S, Cho WK, Levy MJ, Martin JA, Petersen BT, Topazian MD, Chandrasekhara V, Abu Dayyeh BK. End-stage renal disease is associated with increased post endoscopic retrograde cholangiopancreatography adverse events in hospitalized patients. World J Gastroenterol 2018; 24(41): 4691-4697
URL: https://www.wjgnet.com/1007-9327/full/v24/i41/4691.htm
DOI: https://dx.doi.org/10.3748/wjg.v24.i41.4691